文献速递淋巴瘤

伯基特淋巴瘤的靶向治疗:正在研究中的小分子抑制剂

Targeted therapy in Burkitt lymphoma: Small molecule inhibitors under investigation.
PubMed 文献 · Br J Haematol · 2024-04-05

多药化学免疫治疗仍是伯基特淋巴瘤的标准治疗,多数患者可获治愈,但前线方案治疗相关毒性风险显著,老年和免疫抑制患者尤甚,复发/难治患者预后仍差。本文基于成人伯基特淋巴瘤发生中反复出现的基因组改变和信号通路异常,讨论正在研究中的小分子抑制剂靶向治疗策略。

要点

  • 多药化学免疫治疗仍是伯基特淋巴瘤标准治疗,多数病例可治愈。
  • 前线方案治疗相关毒性风险显著,老年和免疫抑制患者尤甚。
  • 复发/难治伯基特淋巴瘤预后仍差,需要新型治疗。

核心结论

  • 基于对成人伯基特淋巴瘤发生中反复基因组改变和信号通路异常的认识,小分子抑制剂靶向治疗策略可能为未来治疗格局开辟道路。

研究设计与样本

  • 综述,讨论基于伯基特淋巴瘤基因组改变和信号通路异常的小分子抑制剂靶向治疗。

主要发现

  • 与伯基特淋巴瘤发生相关的反复基因组改变和信号通路异常包括细胞周期失调、细胞增殖、凋亡抑制、表观遗传失调和张力性B细胞受体-磷脂酰肌醇3-激酶(BCR-PI3K)信号。

临床怎么用

  • 多药化学免疫治疗仍是伯基特淋巴瘤的标准治疗,多数病例可治愈。
  • 前线治疗 regimens 与显著治疗相关毒性风险相关,老年和免疫抑制患者尤甚。
  • 复发/难治伯基特淋巴瘤预后仍差,需要新型治疗以改善结局并减少前线治疗相关毒性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiagent chemoimmunotherapy remains the standard of care treatment for Burkitt lymphoma leading to a cure in the majority of cases. However, frontline treatment regimens are associated with a significant risk of treatment related toxicity especially in elderly and immunocompromised patients. Additionally, prognosis remains dismal in refractory/relapsed Burkitt lymphoma. Thus, novel therapies are required to not only improve outcomes in relapsed/refractory Burkitt lymphoma but also minimize frontline treatment related toxicities. Recurrent genomic changes and signalling pathway alterations that have been implicated in the Burkitt lymphomagenesis include cell cycle dysregulation, cell proliferation, inhibition of apoptosis, epigenetic dysregulation and tonic B-cell receptor-phosphatidylinositol 3-kinase (BCR-PI3K) signalling. Here, we will discuss novel targeted therapy approaches using small molecule inhibitors that could pave the way to the future treatment landscape based on the understanding of recurrent genomic changes and signalling pathway alterations in the lymphomagenesis of adult Burkitt lymphoma.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Atallah-Yunes SA, Habermann TM, Khurana A, et al. Targeted therapy in Burkitt lymphoma: Small molecule inhibitors under investigation. Br J Haematol. 2024. PMID: 38577716. doi:10.1111/bjh.19425

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。